SEARCH | CONTACT US
- Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease
- Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis
- Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.
- Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
- Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
- Salix Resolves Legacy SEC Investigation With No Penalty
- Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
- Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation
- Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies
- US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
- US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets
- Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center
- Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)
- Salix To Highlight New Clinical Data During Digestive Disease Week
- Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
- Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
- Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
- Salix Launches ‘Let’s Talk 2’ IBS Awareness Campaign
- Salix provides update on FDA submission for PLENVU®*
- Salix Announces Filing Acceptance For Plenvu®* Next Generation Bowel Cleansing Preparation For Colonoscopies
- Statement Regarding Xifaxan Intellectual Property Litigation
- Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation
- Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity
- Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor®
- Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit
- Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
- Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada
- Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
- Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
- Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR®
- Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR®
- Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)
- RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
- Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd.
- Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals
- Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021
- Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015
- Valeant And Salix Agree On Amended Terms To Merger Agreement